An observational study in Hepatocellular Carcinoma (HCC), Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by City of Hope Medical Center · Observational
Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensive, or insufficiently sensitive for detecting early-stage disease, and are therefore not suitable for population-wide screening or for simultaneously identifying multiple GI tumor types. As a result, many patients are diagnosed at advanced stages, when therapeutic options are limited and prognosis is poor.
Circulating microRNAs (miRNAs) offer a promising alternative, as they are stable in peripheral blood and reflect tumor-related molecular alterations. In this study, the investigators aim to develop and validate a robust, noninvasive miRNA-based signature capable of distinguishing GI cancers from non-malignant controls. By integrating multi-cohort datasets and applying machine learning-based feature selection and predictive modeling, the investigators will construct a screening panel optimized for reproducibility, scalability, and early-stage detection. This noninvasive miRNA signature has the potential to support accessible, cost-effective, and clinically practical population-level screening for GI cancers, ultimately facilitating earlier diagnosis and improving outcomes for participants.
This study will establish a comprehensive, retrospective, international multi-center cohort consisting of peripheral blood samples from participants with major gastrointestinal cancers-including hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), pancreatic ductal adenocarcinoma (PDAC), esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), and colorectal cancer (CRC)-as well as non-malignant controls. Small RNA sequencing will be performed to generate high-resolution circulating miRNA expression profiles.
During the discovery phase, the investigators will conduct rigorous preprocessing, normalization, batch effect correction, and differential expression analyses to identify circulating miRNAs associated with malignant transformation across GI cancer types. Machine learning-based feature selection (e.g., LASSO, mRMR, ensemble methods) and classifier development (e.g., SVM, Random Forest, XGBoost) will then be used to derive a minimal yet robust miRNA panel capable of optimally distinguishing cancer from non-cancer.
During the modeling and evaluation phase, the identified miRNA signature will undergo multi-center training and validation across international cohorts to ensure robustness across geographic regions, sequencing platforms, and clinical demographics. Beyond binary classification, the investigators will assess the panel's ability to discriminate among specific GI cancer subtypes, thereby supporting differential diagnosis and tumor-origin inference. Model performance will be evaluated using AUROC, sensitivity at clinically meaningful specificity thresholds, early-stage detection capability, and calibration in independent validation cohorts.
Through this sequential discovery → modeling → multi-center validation framework, the investigators aim to develop a noninvasive circulating miRNA panel that (1) accurately distinguishes cancer from non-cancer individuals and (2) differentiates among multiple gastrointestinal cancer types, thereby providing a clinically scalable solution for early cancer detection and population-level screening.
3,182 studies on the registry are indexed under Carcinoma, Hepatocellular; 954 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 754 observational studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →City of Hope Medical Center is the lead sponsor of 670 studies on the registry; 181 are open to participants now.
Of its 30 completed or terminated interventional studies of FDA-regulated products, 12 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult participants (≥18 years) from international multi-center cohorts, including patients with GI cancers (HCC, CCA, PDAC, ESCC, GC, CRC) and non-cancer controls. Blood samples and de-identified clinical data are available for discovery, training, and validation of a circulating miRNA biomarker panel.
Exclusion Criteria:
Patients diagnosed with hepatocellular carcinoma (HCC) confirmed by clinical, imaging, and/or histopathological criteria. Blood samples collected retrospectively from multiple international centers.
Patients diagnosed with cholangiocarcinoma (CCA), including intrahepatic and extrahepatic subtypes, confirmed clinically and/or histopathologically. Blood samples collected retrospectively from multiple international centers.
Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), confirmed by standard diagnostic criteria. Samples collected from multiple international centers.
Patients diagnosed with esophageal squamous cell carcinoma (ESCC). Blood samples collected retrospectively from international collaborating centers.
Patients diagnosed with gastric cancer (GC), confirmed clinically and/or histopathologically. Samples collected from multiple international centers.
Patients diagnosed with colorectal cancer (CRC), confirmed by standard diagnostic methods. Blood samples collected retrospectively from multiple international centers.
Non-cancer individuals, including healthy volunteers and patients with benign gastrointestinal conditions. Blood samples collected from international centers and matched for age and sex where possible.
Diagnostic Accuracy of miRNA Panel
Sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC) for distinguishing GI cancer patients from non-cancer controls.
Time frame: At baseline (pre-treatment blood sample).
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
City of Hope Medical Center